Reference 2018-590

REF:           2018-590

Subject:       Diabetic Macular Oedema

 

Request:

Freedom of information request regarding treatment of patients with Diabetic Macular Oedema.

 

1, How many new patients entered the Diabetic Macular Oedema service in the last 12 Months

 

2, The number of patients receiving drug intervention for the treatment of DMO in the last 12 months

 

3, Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months if possible] with the following drugs for the conditions listed below.

 

 

Diabetic Macular Oedema (Question 3)

Ranibizumab (Lucentis)  
Aflibercept (Eylea)  
Bevacizumab (Avastin)  
Triamcinolone Acetonide  
Dexamethasone (Ozurdex)  
Fluocinalone Acetonide (Iluvien)  
Inflixamab  
Adalimumab  

 

 

Response:

Please find information attached.

2018-590 – FOI Request – Diabetic Macular Oedema [10 kb] MS Excel